Arkolith/Insider Trading/RLMD/Form 4

Traversa Sergio

Chief Executive Officer, DirectorRELMADA THERAPEUTICS, INC. (RLMD) · full profile →Form 4 · filed Dec 16, 2025
Net Buying
Open-Market Buys
$113K
Open-Market Sells
$0
Net Open-Market Flow
$113K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 15, 2025Buy(P)28K$4.12$113K1.3M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 12, 2025Grant(A)1.2M—$01.2M

Transaction Codes

P
Open-market purchase
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-121974) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML